The Life Science Report How to Get Your Piece of the Growing $186B Biomarine Industry: BICA's Pierre Erwes SBOT, ALNEV, FALG
TLSR: Let's talk about some of the public companies advancing in the sector.
PE: One of my favorites, which we have been working with for quite a long time, isStellar Biotechnologies Inc. (SBOT:NASDAQ; KLH:TSX.V), which presented at our last convention in North Carolina.
"Emerging countries could be key actors in the blue economy because many are coastal countries."
While I cannot speak on Stellar’s direct behalf, the company has publicly disclosed the importance of the positive news regarding the agreement with Neovacs SA (ALNEV:Alternext Paris), which I believe will reinforce the demand for Stellar's keyhole limpet hemocyanin (KLH) as a carrier molecule in immunotherapy treatment, such as IFNa-Kinoid in lupus. The trademarked KLH is a key ingredient in clinical-stage immunotherapies targeting metastatic breast cancer (in Phase 3), ovarian cancer (in Phase 2), Alzheimer's disease (in Phase 2), lupus (in Phase 2), and Crohn's disease (in Phase 1).
TLSR: In addition to therapeutic applications, KHL is also being used as an immunodiagnostic test. Where do you see the more immediate value proposition?
PE: In terms of potential market, the pharmaceutical market is definitely the most attractive. If the drug is recognized and the right patent comes at the right time, then it's going to be a gold mine. But the diagnostic market could be accessed more quickly, and it's very well developed already. I think the two directions are very interesting.
TLSR: Stellar just uplisted to NASDAQ. Will that help bring North American investors to the story?
PE: Stellar has stated the listing on the NASDAQ is a significant milestone for the company and an important step in its continued corporate growth and maturity as a public company. Management believes the NASDAQ listing will raise visibility within the investment community and with institutional investors, and will offer its shareholders an opportunity for increased liquidity.